Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 42Rituximab 40Vincristine 31Doxorubicin 29Prednisone 28Etoposide 27Filgrastim 22Peripheral Blood Stem Cell Transplantation 16Radiotherapy 12Ifosfamide 12Cytarabine 12Magnetic Resonance Spectroscopy 10Methotrexate 9Lenalidomide 8Cyclosporine 8Bortezomib 8fludarabine phosphate 7Vorinostat 7Specimen Handling 7Cisplatin 7Carboplatin 7tanespimycin 6ibrutinib 6Melphalan 6Gemcitabine 6Biopsy 6oblimersen 5alvocidib 5aldesleukin 5Oxaliplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Large B-Cell, Diffuse × Adjuvants, Immunologic × Clear all
NCT00024115 2015-04-28

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡